Conditions: Psoriasis Vulgaris
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 219
Healthy volunteers: no

Brief summary:
To gather insight on how product attributes affect usability by investigating the factors that are thought to influence patient preference to topical anti-psoriatic treatments.

Detailed description:
An international, multi-centre, prospective, open-label, randomised, 2-arm, cross-over study with 14-days once daily treatment in subjects with psoriasis vulgaris. To gather insight on how product attributes affect usability by investigating the factors that are thought to influence patient preference to topical anti-psoriatic treatments.

Arms:
arm 1: Day 1 to 7: LEO 90100 aerosol foam Day 8 to 14: Daivobet® gel arm 2: Day 1 to 7: Daivobet® gel Day 8 to 14: LEO 90100 aerosol foam

Interventions: intervention 1: LEO 90100 Aerosol Foam intervention 2: Daivobet® gel
Intervention descriptions: intervention 1: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week intervention 2: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.

Protocol document: